25B-NBOMe (NBOMe-2C-B, BOM 2-CB, Cimbi-36) is a derivative of the phenethylamine hallucinogen 2C-B, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent partial agonist for the 5HT2A receptor.[1][2][3][4] Anecdotal reports from human users suggest 25B-NBOMe to be an active hallucinogen at a dose of as little as 400-650mcg insufflated, making it a similar potency to other phenethylamine derived hallucinogens such as bromo-dragonfly